HIGHLIGHTS
- who: Andrea Boutros and colleagues from the Universitario di Modena, Italy Internal Medicine and Medical Specialities, School of Medicine, University of, Italy have published the paper: Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients, in the Journal: (JOURNAL) of 26/07/2022
SUMMARY
The patient, identified as having intermediate risk according to the International mRCC Database Consortium (IMDC) criteria due to the presence of metastases at diagnosis of renal cell carcinoma (RCC), was then started on pembrolizumab 200 mg every 3 weeks plus axitinib 5 mg twice daily . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.